Abstract:
:Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysis, we retrospectively investigated the outcome of older patients with newly diagnosed MM in an unselected patient population with a special focus on the use of novel agents in a routine care community-based, non-university setting. A total of 107 patients older than 65 years of age or patients aged 60-65 years with relevant comorbidities precluding the use of autologous stem cell transplantation diagnosed with MM between 2000 and 2011 at the two largest non-university hospitals of Eastern Switzerland were analyzed. Patients were grouped into two six-year periods by date of initial diagnosis, 2000-2005 and 2006-2011. The median follow-up was 6.9 (range of 2.1 to 9.4) years. The median OS for the entire cohort was 3.0 years (95% confidence interval, 2.4-4.4). The median OS was significantly longer for patients in the 2006-2011 group (4.3 years) compared with the 2000-2005 group (2.6 years, p = 0.04). The 5-year estimated OS improved from 26% to 38%; 1-year survival was similar in both groups (86% in the 2000-2005 group and 84% in the 2006-2011 group respectively). The use of novel agents showed a statistically significant correlation with OS, whereas the impact of age was only of borderline significance. In conclusion, we demonstrate improved OS outcomes in an unselected population of older patients with MM during the last decade. This improvement is associated with an increased use of novel agents for the treatment of transplant-ineligible MM patients in daily clinical practice. Copyright © 2015 John Wiley & Sons, Ltd.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Mey UJ,Leitner C,Driessen C,Cathomas R,Klingbiel D,Hitz Fdoi
10.1002/hon.2205subject
Has Abstractpub_date
2016-12-01 00:00:00pages
217-223issue
4eissn
0278-0232issn
1099-1069journal_volume
34pub_type
杂志文章abstract::Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.991
更新日期:2011-12-01 00:00:00
abstract::Twenty-three patients (16 adults) failing their first or subsequent (n = 8) intensive treatment for de novo acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia lymphoid blast phase (n = 2) were managed with protocol POG 8201, originally introduced in relapsed ALL of childhood. In this programme, a four-dru...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900100206
更新日期:1992-03-01 00:00:00
abstract::Composite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important becau...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2129
更新日期:2015-03-01 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.1017
更新日期:2012-09-01 00:00:00
abstract::There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析
doi:10.1002/hon.2015
更新日期:2013-03-01 00:00:00
abstract::The management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with singl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900050207
更新日期:1987-04-01 00:00:00
abstract::Mucosa-associated lymphoid tissue (MALT) lymphoma is a radiosensitive malignancy. We report on a case of severe retinopathy following radiation therapy with a moderate dose for orbital MALT lymphoma. A 69-year-old woman with orbital MALT lymphoma received definitive radiation therapy with a total dose of 36 Gy in 18 f...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2124
更新日期:2014-12-01 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2572
更新日期:2019-04-01 00:00:00
abstract::The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199708)15:3<109::aid-hon60
更新日期:1997-08-01 00:00:00
abstract::This report summarizes a closed workshop cosponsored by the American Association for Cancer Research, the European School of Oncology, and the 15th-International Conference on Malignant Lymphoma to discuss critical open questions on liquid biopsy in lymphoid malignancies, develops a roadmap for their analytical and cl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2704
更新日期:2020-02-01 00:00:00
abstract::Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2809
更新日期:2020-09-25 00:00:00
abstract::Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/(sici)1099-1069(1998030)16:1<33::aid-hon62
更新日期:1998-03-01 00:00:00
abstract::In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199912)17:4<149::aid-hon64
更新日期:1999-12-01 00:00:00
abstract::The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/(sici)1099-1069(199702)15:1<3::aid-hon583>
更新日期:1997-02-01 00:00:00
abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2711
更新日期:2020-08-01 00:00:00
abstract::Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900030107
更新日期:1985-01-01 00:00:00
abstract::The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080303
更新日期:1990-05-01 00:00:00
abstract::Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Bo...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2585
更新日期:2019-06-01 00:00:00
abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2378
更新日期:2017-12-01 00:00:00
abstract::There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900100602
更新日期:1992-11-01 00:00:00
abstract:BACKGROUND:A subset of patients with non-Hodgkin's lymphoma (NHL) with clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus without any target lesion to judge the immediate effectiveness of immediately applied additional treatment ...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/(sici)1099-1069(199705)15:2<53::aid-hon598
更新日期:1997-05-01 00:00:00
abstract::The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2547
更新日期:2019-02-01 00:00:00
abstract::Bone marrow (BM) is accepted as the tissue of choice for the detection of monoclonal populations in leukemias and lymphomas; however, obtaining BM can be painful and traumatic for the patients. Although it is possible to detect clonality in peripheral blood (PB) samples, there are no reports comparing the results obse...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.701
更新日期:2003-03-01 00:00:00
abstract::Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2162
更新日期:2016-03-01 00:00:00
abstract::We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.733
更新日期:2004-09-01 00:00:00
abstract::Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2483
更新日期:2018-02-01 00:00:00
abstract::Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.792
更新日期:2006-12-01 00:00:00
abstract::The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We search...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2192
更新日期:2016-06-01 00:00:00
abstract::From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/(sici)1099-1069(199809)16:3<117::aid-hon63
更新日期:1998-09-01 00:00:00
abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2298
更新日期:2017-09-01 00:00:00